Ribbon Acquisition is a SPAC — a shell company with no operations or revenue — formed solely to identify and merge with a private business, taking it public in the process. Ribbon raised $50M in its IPO in January 2025, placing the proceeds into a trust account. The company has since signed a Business Combination Agreement with DRC Medicine, a pharmaceutical company, on June 30, 2025, and is focused on closing that transaction. The SPAC model works by offering private businesses an alternative path to U.S. public markets: by merging with Ribbon, a private company becomes publicly listed on Nasdaq with access to Ribbon's trust capital. Ribbon's sponsor received "founder shares" — Class B shares issued for nominal consideration — that convert into Class A shares only upon deal close, incentivizing the management team to complete a transaction. Public shareholders who dislike the deal can redeem their shares for approximately $10 per share. If no deal closes within the allotted timeframe, Ribbon must liquidate and return trust funds to public shareholders; shareholders have already voted to extend the original December 2025 deadline.